Search Results 111-120 of 17309 for protein intake optimization

1. A Study Of Belantamab Mafodotin Administered In Combination With Lenalidomide And Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, And Dexamethasone (DRd) In Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible For Autologous Stem Cell Transplantation (TI-NDMM) - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... Capable of giving signed informed consent, which includes compliance with the requirements and restrictions ...

2. Lenalidomide and Low-Dose Dexamethasone in Patients with Previously Treated Multiple Myeloma and Kidney Dysfunction - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... Serum monoclonal protein ≥1 g by protein electrophoresis ... Psychiatric illness/social situation that would ...

3. Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... Treated brain metastases are defined as having no ongoing requirement ... Urine protein to creatinine (UPC) ...

4. Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... requirements of the REVLIMID REMS program ... protein, and skin changes); Other prior malignancy ...

5. A Study to Evaluate Pembrolizumab, Ixazomib Citrate, and Dexamethasone to Treat Participants with Relapsed Multiple Myeloma - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... Serum monoclonal protein ≥ 1.0 g/dL;; ≥ 200 mg ... Has known psychiatric or substance abuse disorders that ...

6. Letrozole After Tamoxifen in Treating Women With Breast Cancer - Mayo Clinic

   ... optimal dosages and risks/benefits. ... Estrogen or progesterone receptor positive as defined by tumor receptor content at least 10 fmol/mg protein or receptor ...

7. An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... Serum M-protein ≥1 g/dL (≥10 g/L); OR; Urine M ... Patient is willing and able to adhere to the study visit ...

8. Controlled Trial Evaluating Avacopan in C3 Glomerulopathy - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... requirements of the study protocol; Judged to be ... protein electrophoresis or immunofixation assay.

9. A Study to Evaluate Tadalafil and Lenalidomide with or without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma - Mayo Clinic

   ... optimal dosages and risks/benefits. In the later ... Meet all institutional requirements for autologous stem cell transplantation. ... POEMS syndrome (plasma cell ...

10. A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later ... Serum M-protein ≥ 1 g/dL ( ≥10 g/L); Urine M ... Patient is willing and able to adhere to the study visit ...